DBV Technologies S.A.
NASDAQ:DBVT · NASDAQ Global Select
-$0.16 today
Vol 0.32M · Avg 0.24M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$146.9M -29.0% | -$113.9M -56.6% | -$72.7M +24.5% | -$96.3M +1.6% | -$97.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $3.2M +445.3% | -$925.0K +93.4% | -$14.0M -206.4% | $13.2M +57.1% | $8.4M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $184.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $5.4M +16.6% | $4.6M -23.2% | $6.0M +19.8% | $5.0M +61.0% | $3.1M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $1.3M -76.6% | $5.8M +503.6% | $953.0K -95.7% | $22.3M +198.0% | -$22.8M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 -100.0% | $2.1M | $592.6M | $1.3B | $626.2M |
| Inventory | -$16.1M | $0 | $0 | $0 +100.0% | -$16.2M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $15.8M +5720.5% | $272.0K -96.8% | $8.4M +143.6% | $3.5M +145.7% | -$7.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $1.6M -70.4% | $5.5M +173.4% | -$7.5M -139.6% | $18.9M +1691.9% | -$1.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $15.8M +528128.5% | -$3.0K -103.0% | $99.0K +50.0% | $66.0K -89.9% | $656.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$121.2M -16.0% | -$104.5M -31.2% | -$79.7M -43.0% | -$55.7M +48.5% | -$108.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$533.6K +77.2% | -$2.3M -245.8% | -$677.0K +10.2% | -$754.0K +17.9% | -$918.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 -100.0% | $7.6K -98.5% | $511.0K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 +100.0% | -$285.0K -131.7% | -$123.0K -3.4% | -$119.0K | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 -100.0% | $154.0K -80.0% | $770.0K +250.7% | -$511.0K | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$829.3K -152.5% | $1.6M +1306.9% | -$131.0K -21340.3% | -$611 -100.1% | $604.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$1.4M -80.8% | -$757.0K +6.3% | -$808.0K -708.0% | -$100.0K +76.9% | -$433.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 +100.0% | -$474.0K +18.7% | -$582.9K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $277.0M +43596.6% | $634.0K -90.8% | $6.9M -96.4% | $194.6M +19797.1% | $978.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 +100.0% | -$47.0K +69.5% | -$154.0K | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$854.6K | $0 | $0 +100.0% | -$20.0K +83.5% | -$121.1K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $276.2M +46949.7% | $587.0K -91.3% | $6.8M -96.5% | $194.1M +70739.4% | $274.0K | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $8.1M +289.3% | -$4.3M -172.7% | $5.9M +190.3% | -$6.5M +39.0% | -$10.7M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $161.7M +248.5% | -$108.9M -60.6% | -$67.8M -151.4% | $131.9M +210.8% | -$119.1M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$121.2M -13.4% | -$106.8M -33.0% | -$80.3M -42.3% | -$56.5M +48.3% | -$109.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$851.55M
Alto Neuroscience, Inc.
NYSE:ANRO
$778.73M
Annexon, Inc.
NASDAQ:ANNX
$585.91M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$387.62M
Amarin Corporation plc
NASDAQ:AMRN
$334.13M
Cellectis S.A.
NASDAQ:CLLS
$311.28M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$299.99M
Altimmune, Inc.
NASDAQ:ALT
$239.35M
Korro Bio, Inc.
NASDAQ:KRRO
$125.51M
enGene Holdings Inc.
NASDAQ:ENGN
$88.06M
SEC Filings
Recent regulatory filings
No filings found.
Does DBVT generate free cash flow?
DBV Technologies S.A. (DBVT) generated -$121,181,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does DBVT produce?
Operating cash flow was -$121,181,000.00, before capital expenditures of $533,642.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.